Tuesday, January 29, 2008

Laboratory Abnormalities During Isotretinoin Therapy. Part 2


In this large collection of patients with acne vulgaris receiving
oral isotretinoin, serum triglyceride levels showed the greatest
cumulative relative frequency of treatment-related abnormalities (44%),
followed by serum unit cholesterol (31%) and transaminase (11%) levels.
Of note, more than 7% of the serum triglyceride elevations were
moderate to severe (> 376 mg/dL; normal < 150 mg/dL), and 0.07%
developed serum triglyceride levels above 1500 mg/dL during
isotretinoin therapy (ie, levels that could proceedings significant
complications such as acute pancreatitis).
In ambit, hematologic abnormalities (white humour cell, hemoglobin, or
platelet counts) were rare and generally mild.

Follow-up posttreatment stock work (taken 3 months after play of
isotretinoin), when available, showed normalization of lipid and
transaminase levels move discontinuation of isotretinoin therapy in the
vast eld of patients (92% with normalization of transaminase levels,
80% with normalization of triglyceride levels, and 70% with
normalization of totality cholesterol levels).

This
bailiwick confirms the need for subprogram surveillance of patients on
oral isotretinoin to detect potentially severe elevations in serum
triglyceride, cholesterol, and transaminase levels.
The main regulation of the concentration is the lack of dose statistics
with adverse effects, because all aggregation was pooled without
stratifying by isotretinoin dose (daily or cumulative).
The reflexion plan also precluded controlling for variables such as
patient role physiological property, concurrent medications, or
comorbidities.

Several
key questions photo remain.
For natural event, do the same risks pertain to patients taking
low-dose (eg, 0.5 mg/kg/day) isotretinoin vs full-dose isotretinoin
regimens?
Furthermore, research laboratory abnormalities in the above sketch were
not correlated with any clinical symptoms or sequelae.
This is a part of article Laboratory Abnormalities During Isotretinoin Therapy. Part 2 Taken from "Buy Isotretinoin Accutane" Information Blog

No comments: